Meet with Ontada
at ASH Annual Meeting 2024
December 7-10 | San Diego (San Diego Convention Center)
VISIT US AT BOOTH 2132
ASH is rapidly approaching, and we look forward to connecting. To meet with us at ASH and learn more about Ontada's real-world oncology data, research offerings and provider education solutions, fill out the form or stop by Booth #2132 to chat.
We will be providing demos of two new solutions ON.Path, a provider workflow tool and our ON.Sight feasibility and visualization tool.
We will be hosting demos at our booth during the following times:
- Saturday, Dec. 7: 11 a.m. - 5 p.m.
- Sunday, Dec. 8: 10 a.m. - 5 p.m.
- Monday, Dec. 9: 10 a.m. - noon
For information about our research being presented, simply scroll down on this page.
Co-Presenters of Two Posters:
Ontada Poster Presentations:
Real-world Utilization of Bispecific Antibodies for Treatment of Relapsed/Refractory Multiple Myeloma in the US Community Oncology Setting
Trends in Real-world Characteristics and Outcomes of Patients with Diffuse Large B-cell Lymphoma Treated in the US Community Oncology Setting Pre- and Post-CAR-T Approvals
Saturday, December 7
5:30 PM - 7:30 PM
Poster
Real-world Utilization of Bispecific Antibodies for Treatment of Relapsed/Refractory Multiple Myeloma in the US Community Oncology Setting
-
Lisa Herms, PhD; Zhaohui Su, PhD; Jessica K. Paulus, ScD; Ira Zackon, MD
Sunday, December 8
6:00 PM - 8:00 PM
Poster
Trends in Real-world Characteristics and Outcomes of Patients with Diffuse Large B-cell Lymphoma Treated in the US Community Oncology Setting Pre- and Post-CAR-T Approvals
-
Lisa Herms, PhD; Zhaohui Su, PhD; Jessica K. Paulus, ScD; Ira Zackon, MD
Saturday, December 7
5:30 PM - 7:30 PM
Poster
Real-World Baseline Characteristics and Preliminary Outcomes in Patients with Myelofibrosis Treated with Momelotinib in the US Community Oncology Practice Setting
-
Luke Fletcher, Nicole Niehoff, Sneha Sura, Tom Liu, Karen Todoroff, Shiyuan Zhang, Ira Zackon
ONLINE PUBLICATIONS
Demographics and Mortality of Patients Diagnosed with Multiple Myeloma Treated in the US Community Oncology Setting from 2018 to 2023: Assessing Trends in the Pre-, Peri- and Post-Pandemic Eras
Authors:
Lisa Herms, PhD; Zhaohui Su, PhD; Jessica K. Paulus, ScD; Ira Zackon, MD
The Evolution of Treatment Patterns for Chronic Lymphocytic Leukemia (CLL): Trends in the US Community Oncology Setting from 2015 to 2024
Authors:
Zhaohui Su, PhD; Lisa Herms, PhD; Jessica K. Paulus, ScD; Ira Zackon, MD
Treatment with Zanubrutinib in Patients with Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma Who Were Previously Treated with Another Bruton Tyrosine Kinase Inhibitor in a US Community Oncology Setting
Authors:
David Andorsky MD, Christina Dunbar MSN, Brittani Wayne MPH, Chuck Wentworth MS, Yunfei Wang PhD, Scott Goldfarb PharmD MBA MS-HEOR, Ronda Copher PhD, Mark Balk PharmD MS BCPS, Gregory Maglinte PhD MPH, Ira Zackon MD
Clinical Outcomes and Adverse Events Among Patients with Chronic Lymphocytic Leukemia/ Small Lymphocytic Lymphoma (CLL/SLL) Initiating First-Line (1L) Ibrutinib: Analysis of Subgroups Receiving Subsequent Second Generation (2G) Bruton Tyrosine Kinase Inhibitors, Non-Bruton Tyrosine Kinase Inhibitor Therapy, or Ibrutinib Retreatment in the US Community Oncology Setting
Authors:
John Burke MD, Ira Zackon MD, Brittani Wayne MPH, Yunfei Wang PhD, John Murphy MS, Jennifer Prescott PhD, Shravanthi Gandra PhD MBA, Siyang Leng MD MS, Enrico de Nigris MSc
Using NLP to Identify CAR T-Cell Therapy Recipients from Oncology Progress Notes
Authors:
Avi Raju MPH, MS, Lisa Herms PhD, Zhaohui Su PhD, Ira Zackon MD, Jessica Paulus ScD
Real-World Treatment Patterns and Molecular Response (MR) Among Patients with Newly Diagnosed Chronic-Phase Chronic Myeloid Leukemia (CML-CP) in a Large Community Oncology Setting
Authors:
Ira Zackon MD, April Beeks MPH, David Wei PhD, Chuck Wentworth MS, Jinhong Guo PhD, Courtney McDermott PhD, Kejal Jadhav MS, Lisa Herms PhD, Andrea Damon PhD, Islam Sadek MD, Christopher Benton MD
Meet Our Team at ASH 2024
Reach out to our team for an ASH meetup or fill out our form. We look forward to seeing you in San Diego!